ALK and non-small cell lung carcinoma: In addition to ICIs, future directions in immunotherapy for ALK-positive NSCLC may include the development of ALK-specific cancer vaccines, which could be used in combination with ALK-TKIs or ICIs to enhance antitumor efficacy against ALK-rearranged NSCLC (Voena et al., 2015).